Evidence map›Paper›PMID 30251395›Full record

ArticlePediatric blood & cancer2018

Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.

Monish R Makena, Hwang Eui Cho, Thinh H Nguyen, Balakrishna Koneru, Dattesh U Verlekar, Ashly Hindle, Min H Kang, C Patrick Reynolds

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Monish R MakenaCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
Hwang Eui ChoCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.ORCID 0000-0001-9220-7225
Thinh H NguyenCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
Balakrishna KoneruCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
Dattesh U VerlekarCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
Ashly HindleCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
Min H KangCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
C Patrick ReynoldsCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.ORCID 0000-0002-2827-8536
Texas Tech University · US

Funding

Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastomaR01CA168699 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI KANG, MIN HEE · 2013 to 2016
$844k
NCI NIH HHS CA168699NCI NIH HHS R01 CA168699
6 · The paper itself

Abstract

backgroundMaintenance therapy with 13-cis-retinoic acid and immunotherapy (given after completion of intensive cytotoxic therapy) improves outcome for high-risk neuroblastoma patients. The synthetic retinoid fenretinide (4-HPR) achieved multiple complete responses in relapse/refractory neuroblastoma in early-phase clinical trials, has low systemic toxicity, and has been considered for maintenance therapy clinical trials. Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase with minimal single-agent clinical response data) is being used for maintenance therapy of neuroblastoma. We evaluated the cytotoxic activity of DFMO and fenretinide in neuroblastoma cell lines. PROCEDURE: We tested 16 neuroblastoma cell lines in bone marrow-level hypoxia (5% O

resultsAt clinically achievable levels (100 μM), DFMO significantly decreased (P < 0.05) polyamine putrescine and achieved modest cytotoxicity (<1 log (90% cytotoxicity). Prolonged exposures (7 days) or culture in 2% and 20% O

conclusionsDFMO as a single agent has minimal cytotoxic activity for neuroblastoma cell lines.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorEflornithineFenretinideHumansInhibitory Concentration 50NeuroblastomaAntineoplastic AgentsEflornithineFenretinidedifluoromethylornithinefenretinidemaintenance therapyneuroblastoma

Identifiers

PMID30251395
PMCPMC9621602
OpenAlexW2892837162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.